Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo‐controlled superiority study (VANISH 306)-Reference-Cited by-同舟云学术

Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo‐controlled superiority study (VANISH 306)

Published:2021-11-08 Issue:3 Volume:129 Page:412-420
ISSN:1470-0328
Container-title:BJOG: An International Journal of Obstetrics & Gynaecology
language:en
Short-container-title:BJOG

Author:

Sobel R¹,Nyirjesy P¹,Ghannoum MA²,Delchev DA³,Azie NE⁴,Angulo D⁵,Harriott IA⁶,Borroto‐Esoda K⁷,Sobel JD⁸

Affiliation:

1. Department of Obstetrics and Gynecology Jefferson Vulvovaginal Health Center Sidney Kimmel Medical College Thomas Jefferson University Philadelphia PA USA

2. Department of Dermatology Center for Medical Mycology Case Western Reserve University and University Hospitals Cleveland Medical Center Cleveland OH USA

3. Department of Gynaecology MHAT Dr. Bratan Shukerov AD Smolyan Bulgaria

4. Departments of Clinical Development and Medical Affairs SCYNEXIS, Inc. Jersey City NJ USA

5. Department of Clinical Research SCYNEXIS, Inc. Jersey City NJ USA

6. Department of Medical Affairs SCYNEXIS, Inc. Jersey City NJ USA

7. KBE Consulting Raleigh NC USA

8. Infectious Diseases Department of Internal Medicine Wayne State University Detroit MI USA

Publisher

Wiley

Subject

Obstetrics and Gynecology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1471-0528.16972